サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1363790

喘息・COPD治療薬の世界市場規模調査・予測、疾患別、薬剤クラス別、地域別分析、2023-2030年

Global Asthma and COPD Drugs Market Size Study & Forecast, by Diseases, by Medication Class, and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
喘息・COPD治療薬の世界市場規模調査・予測、疾患別、薬剤クラス別、地域別分析、2023-2030年
出版日: 2023年10月04日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

喘息およびCOPD治療薬の世界市場は、2022年に約361億2,000万米ドルと評価され、予測期間2023～2030年には4.64%以上の健全な成長率で成長すると予測されています。

喘息・COPD治療薬は、喘息や慢性閉塞性肺疾患（COPD）などの呼吸器疾患の管理・治療に使用される薬剤です。喘息とCOPDはともに、気道の炎症と狭窄を特徴とする慢性呼吸器疾患であり、喘鳴、息切れ、咳、胸部圧迫感などの症状を引き起こします。喘息およびCOPD治療薬市場は、個別化治療の傾向の高まり、ライフスタイルパターンの変化、医療サービスへのアクセス向上と相まって増加する政府支援などの要因により拡大しています。

加えて、喘息とCOPDの有病率の増加が、世界中で市場成長の触媒として作用しています。喘息とCOPDは慢性呼吸器疾患で、世界的に大きな負担となっています。世界保健機関（WHO）によると、呼吸器疾患感染症は年間約300万人（世界の死亡者数の6％）が死亡する第3の主要死因とされており、COPDによる死亡者の90％近くは中低所得国の70歳代で発生しています。また、約2億6,200万人の患者が喘息に苦しんでいると推定され、小児がよく罹患します。このように、大気汚染、喫煙、高齢化、ライフスタイルの変化などの要因により、これらの疾患の有病率が増加していることが、喘息やCOPDを管理・治療するための効果的な薬剤に対する需要の高まりに寄与しており、これが推定期間中の喘息・COPD治療薬市場の成長を促進しています。さらに、薬剤開発における技術的進歩、喘息およびCOPDに関する意識の高まり、診断技術の向上は、予測期間中に様々な有利な機会をもたらします。しかし、薬剤に伴う副作用や製品承認のための厳しい政府規制が、2023-2030年の予測期間を通じて市場成長の課題となっています。

喘息およびCOPD治療薬の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、研究開発活動の増加、政府および非政府組織による資金提供数の増加により、2022年の市場を独占しました。一方、アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予想されます。ヘルスケア支出の増加、有利な償還政策、高齢化人口の増加、および有利な償還政策が、この地域全体の市場需要を大幅に促進しています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における業界の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

第2章 世界の喘息・COPD治療薬市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 喘息・COPD治療薬の世界市場力学

  • 喘息およびCOPD治療薬市場の影響分析（2020～2030年）
    • 市場促進要因
      • 喘息およびCOPDの有病率の増加
      • 個別化治療の動向の高まり
    • 市場の課題
      • 薬剤に伴う副作用
      • 製品承認のための厳しい政府規制
    • 市場機会
      • 医薬品開発における技術の進歩
      • 診断技術の向上とともに、喘息およびCOPDに対する意識の高まり

第4章 喘息・COPD治療薬の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 疾患別：喘息・COPD治療薬の世界市場

  • 市場スナップショット
  • 気管支喘息およびCOPD治療薬の世界市場：疾患別、実績 - ポテンシャル分析
  • 喘息・COPD治療薬の世界市場：疾患別推定・予測2020～2030年
  • 喘息およびCOPD治療薬の世界市場、サブセグメント分析
    • 喘息
    • COPD

第6章 喘息・COPD治療薬の世界市場：薬剤クラス別

  • 市場スナップショット
  • 薬剤クラス別喘息治療薬およびCOPD治療薬の世界市場、実績 - ポテンシャル分析
  • 喘息・COPD治療薬の世界市場：薬剤クラス別推定・予測（2020-2030年）
  • 喘息治療薬およびCOPD治療薬の世界市場、サブセグメント別分析
    • 配合剤
    • 短時間作用型β作動薬（SABA）
    • 長時間作用型β作動薬（LABA）
    • ロイコトリエン拮抗薬（LTA）
    • 抗コリン薬
    • その他

第7章 喘息・COPD治療薬の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 喘息およびCOPD治療薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • 疾患の推定・予測、2020-2030年
      • 薬効分類の推定・予測、2020-2030年
    • カナダ
  • 欧州喘息・COPD治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋喘息・COPD治療薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの喘息・COPD治療薬市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第8章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Vectura Group Limited
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Abbott Laboratories
    • Glaxosmithkline Plc
    • Sanofi
    • Organon
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd
    • AstraZeneca Plc

第9章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Asthma and COPD Drugs Market, report scope
  • TABLE 2. Global Asthma and COPD Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Asthma and COPD Drugs Market estimates & forecasts by Diseases 2020-2030 (USD Billion)
  • TABLE 4. Global Asthma and COPD Drugs Market estimates & forecasts by Medication Class 2020-2030 (USD Billion)
  • TABLE 5. Global Asthma and COPD Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Asthma and COPD Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Asthma and COPD Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Asthma and COPD Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Asthma and COPD Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Asthma and COPD Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Asthma and COPD Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Asthma and COPD Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Asthma and COPD Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Asthma and COPD Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. U.S. Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. Canada Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 19. Canada Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. Canada Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. UK Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 22. UK Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. UK Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. Germany Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 25. Germany Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. Germany Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. France Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 28. France Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. France Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. Italy Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 31. Italy Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Italy Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Spain Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 34. Spain Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. Spain Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. RoE Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 37. RoE Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. RoE Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. China Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 40. China Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. China Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. India Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 43. India Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. India Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. Japan Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 46. Japan Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. Japan Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. South Korea Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 49. South Korea Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. South Korea Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. Australia Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 52. Australia Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. Australia Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. Brazil Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 58. Brazil Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Brazil Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Mexico Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 61. Mexico Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. Mexico Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. RoLA Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 64. RoLA Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. RoLA Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. Saudi Arabia Asthma and COPD Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 67. South Africa Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. RoMEA Asthma and COPD Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Asthma and COPD Drugs Market
  • TABLE 70. List of primary sources, used in the study of global Asthma and COPD Drugs Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Asthma and COPD Drugs Market, research methodology
  • FIG 2. Global Asthma and COPD Drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Asthma and COPD Drugs Market, key trends 2022
  • FIG 5. Global Asthma and COPD Drugs Market, growth prospects 2023-2030
  • FIG 6. Global Asthma and COPD Drugs Market, porters 5 force model
  • FIG 7. Global Asthma and COPD Drugs Market, pest analysis
  • FIG 8. Global Asthma and COPD Drugs Market, value chain analysis
  • FIG 9. Global Asthma and COPD Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Asthma and COPD Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Asthma and COPD Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Asthma and COPD Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Asthma and COPD Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Asthma and COPD Drugs Market, regional snapshot 2020 & 2030
  • FIG 15. North America Asthma and COPD Drugs Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Asthma and COPD Drugs Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Asthma and COPD Drugs Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Asthma and COPD Drugs Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Asthma and COPD Drugs Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Asthma and COPD Drugs Market is valued at approximately USD 36.12 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 4.64% over the forecast period 2023-2030. Asthma and COPD drugs are medications used to manage and treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Both asthma and COPD are chronic respiratory diseases characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, shortness of breath, coughing, and chest tightness. The Asthma and COPD Drugs Market is expanding because of factors such as the growing trend of personalized therapy, changing lifestyle patterns, and increasing government support, coupled with better access to healthcare services.

In addition, the increasing prevalence of asthma and COPD is acting as a catalyzing factor for market growth across the globe. Asthma and COPD are chronic respiratory diseases with a significant global burden. According to the World Health Organization (WHO), respiratory disease infection is considered the third major cause of death with approximately 3 million death per year (6% of global deaths), in which nearly 90% of COPD fatalities occur in those 70-year-old people from the low-and middle-income countries. Also, there are around 262 million patients estimated to suffer from asthma, which commonly affects children. Thus, the increasing prevalence of these conditions, driven by factors such as air pollution, smoking, aging populations, and changing lifestyles, contributes to the growing demand for effective medications to manage and treat asthma and COPD, which, in turn, propelling the growth of the Asthma and COPD Drugs Market during the estimated period. Moreover, the technological advancements in drug development, as well as the increasing awareness about asthma and COPD, along with improved diagnostic techniques present various lucrative opportunities over the forecast years. However, the side effects associated with drugs and stringent government regulations for product approvals are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Asthma and COPD Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing research and development activities, along with the rise in the number of fundings undertaken by government and non-government organizations. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The rising healthcare expenditure, favorable reimbursement policies, increasing aging population, as well as favorable reimbursement policies are significantly propelling the market demand across the region.

Major market players included in this report are:

  • Vectura Group Limited
  • Abbott Laboratories
  • Glaxosmithkline Plc
  • Sanofi
  • Organon
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd
  • AstraZeneca Plc

Recent Developments in the Market:

  • In October 2022, Verona reported positive analyses of Ensifentrine, a medication used to treat chronic obstructive pulmonary disease (COPD), which was the subject of a phase 3 clinical trial. Ensifentrine combines bronchodilator and anti-inflammatory properties into a single substance.
  • In June 2022, Glenmark introduced the innovative fixed dose combination (FDC) medication Indacaterol with Mometasone for patients in India with unmanageable asthma. This FDC was introduced by the business under the Indamet brand.

Global Asthma and COPD Drugs Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Diseases, Medication Class, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Diseases:

  • Asthma
  • COPD

By Medication Class:

  • Combination Drugs
  • Short Acting Beta Agonists (SABA)
  • Long Acting Beta Agonists (LABA)
  • Leukotriene Antagonists (LTA)
  • Anticholinergics
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Asthma and COPD Drugs Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Asthma and COPD Drugs Market, by Diseases, 2020-2030 (USD Billion)
    • 1.2.3. Asthma and COPD Drugs Market, by Medication Class, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Asthma and COPD Drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Asthma and COPD Drugs Market Dynamics

  • 3.1. Asthma and COPD Drugs Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of asthma and COPD
      • 3.1.1.2. Rising trend of personalized therapy
    • 3.1.2. Market Challenges
      • 3.1.2.1. Side effects associated with drugs
      • 3.1.2.2. Stringent government regulations for product approvals
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Technological advancements in drug development
      • 3.1.3.2. Increasing awareness about asthma and COPD, along with improved diagnostic techniques

Chapter 4. Global Asthma and COPD Drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Asthma and COPD Drugs Market, by Diseases

  • 5.1. Market Snapshot
  • 5.2. Global Asthma and COPD Drugs Market by Diseases, Performance - Potential Analysis
  • 5.3. Global Asthma and COPD Drugs Market Estimates & Forecasts by Diseases 2020-2030 (USD Billion)
  • 5.4. Asthma and COPD Drugs Market, Sub Segment Analysis
    • 5.4.1. Asthma
    • 5.4.2. COPD

Chapter 6. Global Asthma and COPD Drugs Market, by Medication Class

  • 6.1. Market Snapshot
  • 6.2. Global Asthma and COPD Drugs Market by Medication Class, Performance - Potential Analysis
  • 6.3. Global Asthma and COPD Drugs Market Estimates & Forecasts by Medication Class 2020-2030 (USD Billion)
  • 6.4. Asthma and COPD Drugs Market, Sub Segment Analysis
    • 6.4.1. Combination Drugs
    • 6.4.2. Short Acting Beta Agonists (SABA)
    • 6.4.3. Long Acting Beta Agonists (LABA)
    • 6.4.4. Leukotriene Antagonists (LTA)
    • 6.4.5. Anticholinergics
    • 6.4.6. Others

Chapter 7. Global Asthma and COPD Drugs Market, Regional Analysis

  • 7.1. Top Leading Countries
  • 7.2. Top Emerging Countries
  • 7.3. Asthma and COPD Drugs Market, Regional Market Snapshot
  • 7.4. North America Asthma and COPD Drugs Market
    • 7.4.1. U.S. Asthma and COPD Drugs Market
      • 7.4.1.1. Diseases breakdown estimates & forecasts, 2020-2030
      • 7.4.1.2. Medication Class breakdown estimates & forecasts, 2020-2030
    • 7.4.2. Canada Asthma and COPD Drugs Market
  • 7.5. Europe Asthma and COPD Drugs Market Snapshot
    • 7.5.1. U.K. Asthma and COPD Drugs Market
    • 7.5.2. Germany Asthma and COPD Drugs Market
    • 7.5.3. France Asthma and COPD Drugs Market
    • 7.5.4. Spain Asthma and COPD Drugs Market
    • 7.5.5. Italy Asthma and COPD Drugs Market
    • 7.5.6. Rest of Europe Asthma and COPD Drugs Market
  • 7.6. Asia-Pacific Asthma and COPD Drugs Market Snapshot
    • 7.6.1. China Asthma and COPD Drugs Market
    • 7.6.2. India Asthma and COPD Drugs Market
    • 7.6.3. Japan Asthma and COPD Drugs Market
    • 7.6.4. Australia Asthma and COPD Drugs Market
    • 7.6.5. South Korea Asthma and COPD Drugs Market
    • 7.6.6. Rest of Asia Pacific Asthma and COPD Drugs Market
  • 7.7. Latin America Asthma and COPD Drugs Market Snapshot
    • 7.7.1. Brazil Asthma and COPD Drugs Market
    • 7.7.2. Mexico Asthma and COPD Drugs Market
  • 7.8. Middle East & Africa Asthma and COPD Drugs Market
    • 7.8.1. Saudi Arabia Asthma and COPD Drugs Market
    • 7.8.2. South Africa Asthma and COPD Drugs Market
    • 7.8.3. Rest of Middle East & Africa Asthma and COPD Drugs Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. Company 1
    • 8.1.2. Company 2
    • 8.1.3. Company 3
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Vectura Group Limited
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summaryd
      • 8.3.1.5. Recent Developments
    • 8.3.2. Abbott Laboratories
    • 8.3.3. Glaxosmithkline Plc
    • 8.3.4. Sanofi
    • 8.3.5. Organon
    • 8.3.6. F. Hoffmann-La Roche AG
    • 8.3.7. Novartis AG
    • 8.3.8. Boehringer Ingelheim International GmbH
    • 8.3.9. Teva Pharmaceutical Industries Ltd
    • 8.3.10. AstraZeneca Plc

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption